Theratechnologies Inc. (NASDAQ:THTX) Sees Significant Increase in Short Interest

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 43,000 shares, an increase of 26.8% from the October 15th total of 33,900 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 33,400 shares, the short-interest ratio is presently 1.3 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Theratechnologies stock. Cyndeo Wealth Partners LLC increased its position in Theratechnologies Inc. (NASDAQ:THTX) by 26.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 131,311 shares of the company’s stock after purchasing an additional 27,191 shares during the quarter. Cyndeo Wealth Partners LLC owned approximately 0.29% of Theratechnologies worth $163,000 as of its most recent SEC filing.

Theratechnologies Trading Down 2.5 %

NASDAQ THTX opened at $1.18 on Friday. Theratechnologies has a 1-year low of $1.08 and a 1-year high of $2.58. The company has a 50 day moving average of $1.25 and a 200-day moving average of $1.31. The firm has a market cap of $54.26 million, a price-to-earnings ratio of -11.80 and a beta of 1.41.

Theratechnologies (NASDAQ:THTX) last issued its quarterly earnings data on Thursday, October 10th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $22.60 million during the quarter. During the same period last year, the firm posted ($0.03) EPS. On average, analysts forecast that Theratechnologies will post 0.03 earnings per share for the current year.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.